Loading...
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Fuhr, Viktoria Vafadarnejad, Ehsan Dietrich, Oliver Arampatzi, Panagiota Riedel, Angela Saliba, Antoine-Emmanuel Rosenwald, Andreas Rauert-Wunderlich, Hilka
Fuhr, Viktoria
Vafadarnejad, Ehsan
Dietrich, Oliver
Arampatzi, Panagiota
Riedel, Angela
Saliba, Antoine-Emmanuel
Rosenwald, Andreas
Rauert-Wunderlich, Hilka
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-02-25
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 17.76 MB
Other Titles
Abstract
Since the approval of ibrutinib for relapsed/refractory mantle cell lymphoma (MCL), the treatment of this rare mature B-cell neoplasm has taken a great leap forward. Despite promising efficacy of the Bruton tyrosine kinase inhibitor, resistance arises inevitably and the underlying mechanisms remain to be elucidated. Here, we aimed to decipher the response of a sensitive MCL cell line treated with ibrutinib using time-resolved single-cell RNA sequencing. The analysis uncovered five subpopulations and their individual responses to the treatment. The effects on the B cell receptor pathway, cell cycle, surface antigen expression, and metabolism were revealed by the computational analysis and were validated by molecular biological methods. The observed upregulation of B cell receptor signaling, crosstalk with the microenvironment, upregulation of CD52, and metabolic reprogramming towards dependence on oxidative phosphorylation favor resistance to ibrutinib treatment. Targeting these cellular responses provide new therapy options in MCL.
Citation
Int J Mol Sci. 2021 Feb 25;22(5):2276. doi: 10.3390/ijms22052276.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1422-0067
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International